Multicenter, phase III, open-label, randomized study in relapsed/refractory CLI, to evaluate the benefit of GDC-0199 (ABT-199) plus rituximah compared with bendamustine plus rituximab.

被引：2
|
作者：
Mobasher, Mehrdad
Huang, Jane
Elstrom, Rebecca L.
Elhamy, Mostafa
Bernaards, Coen
Hallek, Michael J.
Hillmen, Peter
Kater, Arnon Philip
Kipps, Thomas J.
Seymour, John Francis
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Cologne, D-50931 Cologne, Germany
[3] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
[4] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps7120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7120
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Swinnen, Lode
    Kozloff, Mark
    Wang, Ding
    Reid, Erin
    Nastoupil, Loretta
    Fowler, Nathan
    Cordero, Jaclyn
    D'Amico, Diane
    Diehl, Susan
    Dunbar, Martin
    Zhu, Ming
    Wong, Shekman
    Enschede, Sari Heitner
    Chien, David
    Humerickhouse, Rod A.
    Flowers, Christopher
    BLOOD, 2015, 126 (23)
  • [2] The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Flowers, Christopher R.
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan
    Reid, Erin
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Yang, Jianning
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod A.
    Kozloff, Mark
    BLOOD, 2014, 124 (21)
  • [3] IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PHASE 2, OPEN-LABEL STUDY OF VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY
    Wierda, W.
    Sail, K.
    Noe, L.
    Kamalakar, R.
    Gdovin, J.
    Verdugo, M.
    Kim, S.
    Humerickhouse, R.
    Stilgenbauer, S.
    HAEMATOLOGICA, 2017, 102 : 599 - 599
  • [4] A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
    Gerecitano, John F.
    Roberts, Andrew W.
    Seymour, John F.
    Wierda, William G.
    Kahl, Brad S.
    Pagel, John M.
    Puvvada, Soham
    Kipps, Thomas J.
    Anderson, Mary Ann
    Dunbar, Martin
    Zhu, Ming
    Gressick, Lori
    Wagner, Lindsay
    Kim, Su Young
    Enschende, Sari Heitner
    Humerickhouse, Rod A.
    Davids, Matthew S.
    BLOOD, 2015, 126 (23)
  • [5] Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy
    Jones, Jeffrey
    Mato, Anthony R.
    Coutre, Steven
    Wierda, William
    Choi, Michael Y.
    Davids, Matthew S.
    Lamanna, Nicole
    Barr, Paul
    Burns, Kim
    Montalvo, Nicholas
    Zhu, Ming
    Busman, Todd
    Potluri, Jalaja
    Humerickhouse, Rod A.
    Byrd, John C.
    BLOOD, 2015, 126 (23)
  • [6] A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphosytic leukemia (CLL) harboring 17p deletion
    Wierda, William G.
    Seymour, John Francis
    Roberts, Andrew Warwick
    Puvvada, Soham
    Davids, Matthew Steven
    Wong, Shekman
    Zhu, Ming
    Carrl, Elisa
    Humerickhouse, Rod
    Stilgenbauer, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles Andre
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Lymp, James
    Hilger, James
    Vosganian, Gregory
    Huang, Jane
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [8] A DOSE-ESCALATION STUDY OF THE BCL-2 INHIBITOR VENETOCLAX (ABT-199/GDC-0199) PLUS BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN'S LYMPHOMA (NHL)
    de Vos, S.
    Flowers, C.
    Wang, D.
    Swinnen, L.
    Fowler, N.
    Reid, E.
    Cordero, J.
    Gifford, M.
    D'Amico, D.
    Dunbar, M.
    Zhu, M.
    Salem, A.
    Enschede, S. H.
    Ricker, J. L.
    Chien, D.
    Humerickhouse, R.
    Kozloff, M.
    HAEMATOLOGICA, 2015, 100 : 4 - 5
  • [9] Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Roberts, Andrew W.
    Ma, Shuo
    Brander, Danielle M.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Davids, Matthew S.
    Anderson, Mary Ann
    Tam, Constantine
    Mason-Bright, Tanita
    Rudersdorf, Nikita K.
    Gressick, Lori
    Yang, Jianning
    Munasinghe, Wijith
    Zhu, Ming
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Seymour, John F.
    BLOOD, 2014, 124 (21)
  • [10] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles A.
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Cartron, Guillaume
    Li, Yan
    Hilger, James
    Mobasher, Mehrdad
    Stilgenbauer, Stephan
    BLOOD, 2015, 126 (23)
12345